Foghorn Therapeutics Inc. - Common Stock (FHTX)
4.1500
-0.1900 (-4.38%)
Foghorn Therapeutics Inc is a biotechnology company that specializes in the development of treatments for cancer and other genetic diseases by focusing on the modulation of gene expression
The company leverages its proprietary Gene Traffic Control platform to create small molecule therapies that specifically target the proteins involved in gene regulation, with the aim of providing more effective and personalized treatment options. By understanding and manipulating the underlying mechanisms of gene activity, Foghorn seeks to address unmet medical needs and improve patient outcomes in challenging therapeutic areas.
This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursdaybenzinga.com
Via Benzinga · January 30, 2025
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 16, 2024
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lowerbenzinga.com
Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program.
Via Benzinga · December 16, 2024
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionbenzinga.com
Via Benzinga · August 19, 2024
What 5 Analyst Ratings Have To Say About Foghorn Therapeuticsbenzinga.com
Via Benzinga · August 7, 2023
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · August 19, 2024
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q2 2024investorplace.com
FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Misses Revenue for Q1 2024investorplace.com
FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 6, 2024
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023investorplace.com
FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 7, 2024
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · February 8, 2024
What 6 Analyst Ratings Have To Say About Foghorn Therapeuticsbenzinga.com
Via Benzinga · June 8, 2023
Why Foghorn Therapeutics (FHTX) Stock Is Exploding Higherbenzinga.com
Foghorn Therapeutics shares are trading higher by 44.8% Thursday. The company announced that Eli Lilly has chosen FHD-909 for clinical development.
Via Benzinga · February 8, 2024
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Sessionbenzinga.com
Gainers Addentax Group Corp. (NASDAQATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top Games-as-a-Service firms.
Via Benzinga · June 30, 2023
Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursdaybenzinga.com
Keybanc boosted the price target for Micron Technology, Inc. (NASDAQMU) from $70 to $80. Keybanc analyst John Vinh maintained an Overweight rating. Micron shares rose 3.9% to $69.70 in pre-market trading.
Via Benzinga · June 29, 2023
Foghorn Therapeutics Shifts Focus from Development Of Cancer Hopeful with Eye Cancerbenzinga.com
Foghorn Therapeutics Inc (NASDAQFHTX) announced the data from the Phase 1 dose escalation safety study of FHD-286 in
Via Benzinga · June 28, 2023
Crude Oil Up 1.5%; Philips Shares Jump After Q1 Resultsbenzinga.com
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 40 points on Monday. The Dow traded up 0.05% to 33,827.42 while the NASDAQ fell 0.33% to 12,032.16. The S&P 500, also fell, dropping, 0.01% to 4,132.91.
Via Benzinga · April 24, 2023
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionbenzinga.com
Gainers Aclarion, Inc. (NASDAQACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment.
Via Benzinga · April 24, 2023
US Stocks Turn Lower; Nasdaq Dips 100 Pointsbenzinga.com
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping around 100 points on Monday. The Dow traded down 0.19% to 33,744.92 while the NASDAQ fell 0.84% to 11,971. The S&P 500, also fell, dropping, 0.32% to 4,120.38.
Via Benzinga · April 24, 2023
More Trouble For Foghorn Therapeutics: After Blood Cancer Trial, FDA Puts Another Cancer Trial On Clinical Holdbenzinga.com
Via Benzinga · April 24, 2023
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · April 24, 2023
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023benzinga.com
Via Benzinga · March 28, 2023